BMS

Key Takeaways •The Phase 3 RELATIVITY-098 trial did not achieve its primary endpoint of recurrence-free survival.•Opdualag’s safety profile remained consistent with existing data.•Opdivo continues as...

Key TakeawaysThe European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Opdivo (nivolumab) combined with Yervoy (ipilimumab)...

Key TakeawaysThe European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Bristol Myers Squibb's CAR T...

Key TakeawaysThe combination of Opdivo (nivolumab) and Yervoy (ipilimumab) significantly reduces disease progression risk in metastatic colorectal cancer patients with specific genetic profiles. ...

Key TakeawaysBristol Myers Squibb (BMS) will present at J.P. Morgan’s 43rd Annual Healthcare Conference on January 13, 2025. A fireside chat and live...

Key TakeawaysSotyktu Phase 3 trials show significant efficacy in Psoriatic Arthritis (PsA). The trials confirm safety consistent with previous studies in psoriasis. Sotyktu...

Key TakeawaysOpdivo Qvantig offers faster subcutaneous administration compared to intravenous treatments. Phase 3 trials confirmed efficacy and comparable safety to IV Opdivo. This...

Key TakeawaysChristopher Boerner, CEO of Bristol Myers Squibb, will participate in a fireside chat at the Citi Global Healthcare Conference. The event is...

Key TakeawaysViz.ai's Viz HCM™ recognized as the Best Digital Health Solution in 2024. The AI-powered tool accelerates the diagnosis of Hypertrophic Cardiomyopathy (HCM). ...

Key TakeawaysImplement value-based reimbursement models to incentivize innovation and improve patient access. Streamline health technology assessments across EU member states to reduce approval...

Key TakeawaysBristol Myers Squibb (BMS) presented over 90 data disclosures at ASH 2024, including breakthroughs in hematology and cell therapy. The presentations underline...

Key TakeawaysOpdivo-Yervoy combination offers a novel first-line treatment option for MSI-H/dMMR metastatic colorectal cancer. Enhanced survival rates could set a new standard in...

Key TakeawaysRepotrectinib shows strong efficacy in treating advanced ROS1-positive NSCLC and NTRK-positive solid tumors. Positive CHMP recommendation paves the way for EU approval...

Key TakeawaysPositive CHMP opinion for Opdivo® and Yervoy® as first-line treatment for metastatic colorectal cancer. The CheckMate -8HW trial showed a 79% reduction...

Key TakeawaysBristol Myers Squibb (BMS) will showcase new clinical and health economics outcomes research (HEOR) data on COBENFY™ for schizophrenia at Psych Congress...